Slow release magnesium composition and uses thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/22
A61K-033/06
A61K-031/195
A61K-031/28
출원번호
US-0736679
(2013-01-08)
등록번호
US-8734855
(2014-05-27)
발명자
/ 주소
Liu, Guosong
Mao, Fei
출원인 / 주소
Magceutics, Inc.
대리인 / 주소
Wilson Sonsini Goodrich and Rosati
인용정보
피인용 횟수 :
8인용 특허 :
19
초록▼
The present invention provides compositions that contain magnesium and threonate, or a threonate precursor molecule, formulated for extended or modified release to provide physiological concentrations over a desired time period. The extended release or modified release form is particularly useful in
The present invention provides compositions that contain magnesium and threonate, or a threonate precursor molecule, formulated for extended or modified release to provide physiological concentrations over a desired time period. The extended release or modified release form is particularly useful in providing Mg to a subject while avoiding adverse side effects such as diarrhea.
대표청구항▼
1. A method of supplementing magnesium in a subject in need thereof, comprising administering an oral dosage form comprising magnesium (Mg) and threonate (T), wherein at least a portion of the magnesium and threonate are complexed in a salt form of MgT2, and further wherein the oral dosage form is a
1. A method of supplementing magnesium in a subject in need thereof, comprising administering an oral dosage form comprising magnesium (Mg) and threonate (T), wherein at least a portion of the magnesium and threonate are complexed in a salt form of MgT2, and further wherein the oral dosage form is a controlled release formulation. 2. The method of claim 1, wherein the oral dose is administered to treat a magnesium deficient condition. 3. The method of claim 2 wherein the magnesium deficient condition is selected from the group consisting of a neurological disorder, a cardiovascular disorder, and a metabolic disorder. 4. The method of claim 1, wherein the oral dose is administered to elevate magnesium in a central nervous system of a subject in need thereof. 5. The method of claim 1, wherein the subject adopts a high calorie diet. 6. The method of claim 1, wherein the oral dosage form is administered to said subject at least twice a day for a period of 1 month or longer. 7. The method of claim 1, wherein the oral dosage form has an in vitro dissolution profile in a dissolution medium; and further wherein the dissolution profile ranges between less than or equal to 5% in about 2 hours, less than 10% in about 4 hours, less than 40% in about 6 hours, greater than or equal to 60% in about 10 hours, and greater than or equal to 80% in about 12 hours as measured using a USP type II paddle dissolution system at 75 rpm, at a temperature of 37° C. 8. The method of claim 1, wherein the oral dosage form has an in vitro dissolution profile in a dissolution medium; and further wherein the dissolution profile ranges between less than 5% in about 2 hours, less than 10% in about 4 hours, less than 40% in about 6 hours, greater than or equal to 60% in about 10 hours, and greater than or equal to 80% in about 12 hours as measured using a USP type II paddle dissolution system at 75 rpm, at a temperature of 37° C. 9. The method of claim 1, wherein the oral dosage form comprises between about 10 mg to 500 mg elemental magnesium (Mg), and further wherein administering the oral dosage form to a Sprague-Dawley rat at a dosage of about 75 mg/kg/day yields an incidence of diarrhea of less than 20%. 10. The method of claim 1, wherein upon administering the oral dosage form to a subject at least 50% of the administered magnesium is absorbed in the subject, or that at least 30% of the magnesium administered to the subject is retained by the subject over a period of at least two days when the oral dosage form is administered at a dose of 20 mg/kg/day or higher. 11. The method of claim 1, wherein the oral dosage form is administered to the subject in an amount effective to reduce the subject's risk of adverse effects of a high calorie diet relative to the subject's risk before treatment, wherein the adverse effect is atherosclerosis, heart disease, myocardial infarction, stroke, thromboembolism, metabolic syndrome, or diabetes. 12. The method of claim 1, wherein the magnesium and threonate in the oral dosage form is encapsulated in a tablet. 13. The method of claim 1, wherein elemental magnesium (Mg) is present in an amount equal to at least 10 mg by weight of the oral dosage form. 14. The method of claim 1, wherein elemental magnesium (Mg) is present in an amount equal to at least 20 mg by weight of the oral dosage form. 15. The method of claim 1, wherein said magnesium (Mg) is present in an amount greater than about 1% by weight of the oral dosage form. 16. The method of claim 1, wherein the oral dosage form further comprises a metal ion selected from the group consisting of calcium, potassium, sodium, chromium, iron, selenium, zinc, manganese, molybdenum, vanadium, and lithium. 17. The method of claim 1, wherein the oral dosage form further comprises one or more antioxidants selected from the group consisting of resveratrol, ellagic acid, quercetin, lipoic acid, and vitamin C. 18. The method of claim 1, wherein the oral dosage form further comprises a polymer binder mixed with the magnesium (Mg) and threonate (T). 19. The method of claim 1, wherein the oral dosage form is administered to a human subject at a dose between about 1 mg elemental magnesium/kg/day to about 16 mg elemental magnesium/kg/day.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (19)
William T. Evans ; Dwight L. McKee, Alkali or alkaline earth metal of n-butyric acid for treatment of cognitive and emotional conditions.
George H. Clark ; Mary Ann Clark, Carbonated fortified milk-based beverage and method of making carbonated fortified milk-based beverage for the supplementation of essential nutrients in the human diet.
Yu Kai,CNX ; Wang Zhiwen,CNX ; Kou Fuping,CNX, L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof.
Skyler Jay S. (Key Biscayne FL) Frost Phillip (Miami Beach FL) Hahn Elliot F. (North Miami Beach FL), Method and composition for treatment of insulin resistance syndromes.
Glick J. Leslie (Potomac MD), Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory lo.
Atalla Rajai H. (Verona WI) Weinstock Ira A. (Madison WI) Hill Craig L. (Atlanta GA) Reiner Richard S. (Madison WI), Oxidation of lignin and polysaccharides mediated by polyoxometalate treatment of wood pulp.
Costa Jonathan L. (Wheaton IL) Diazgranados Jesus A. (Cali COX), Treatment of human diseases involving dysregulation or dysfunction of the nervous system.
Brownell, Lidia Alfaro; Chu, Min; Hong, Mei-Feng; Hyun, Eu-Jin; Jia, Qi; Jiao, Ping; Kim, Hyun-Jin; Kim, Mi-Ran; Kim, Tae-Woo; Lee, Young-Chul; Nam, Jeong-Bum; Yimam, Mesfin, Compositions and methods for managing or improving bone disorders, cartilage disorders, or both.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.